Detalles de la búsqueda
1.
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
Semin Arthritis Rheum
; 65: 152388, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301349
2.
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Arthritis Care Res (Hoboken)
; 74(5): 748-758, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33253491
3.
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
Semin Arthritis Rheum
; 56: 152081, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35985172
4.
Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry.
ACR Open Rheumatol
; 4(10): 872-882, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869686
5.
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081].
Semin Arthritis Rheum
; 58: 152141, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36463635
Resultados
1 -
5
de 5
1
Próxima >
>>